COVID 19
Conditions
Brief summary
When the COVID-19 virus infects a person, it enters the lung epithelial cells of its host and uses its genetic material to replicate. The pulmonary epithelial cells of a part of the population, known as secretors, are capable of expressing the antigens of the ABO system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system. When the virus replicates in an secreting individual, the antigens of the ABO system of the infected individual will be present on the surface of the viruses formed in his/her lungs. It was shown in 2003 that the response of a given individual to the transmission of a virus depends on his/her blood group and on the antigens of the ABO system carried by the virus. A patient of group O would thus defend himself much better against a virus carrying antigens of blood group A, the natural antibodies anti-A of the patient reducing the ability of the virus to bind to its specific receptor on pulmonary epithelial cells, to penetrate them to replicate itself. The first data collected in Wuhan (China) seems to confirm this hypothesis. A COVID-19 virus transmission model can therefore be established on the basis of blood groups. In order to reduce the spread of the virus among nursing staff, it is possible to establish a preferential algorithm for patient management based on the ABO and Lewis blood groups of patients and ABO of nursing staff in health care units, if operational and human conditions allow.
Interventions
DIAGNOSTIC_TESTBlood group determination
Determination of the blood group (ABO/LE)
DIAGNOSTIC_TESTAntibody titration
Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.
DIETARY_SUPPLEMENTProbiotic
Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
Sponsors
Hanane EL KENZ
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* COVID19 positive patients admitted within the CHU Brugmann Hospital
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-A antibody concentration | baseline | Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system. |
| Anti-B antibody concentration | baseline | Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system. |
| Blood group | baseline | Blood group (ABO/LE) |
Countries
Belgium
Outcome results
None listed